Public and private capital is pouring in. Of the $2 trillion stimulus package announced by the US government, $130 billion will go directly to the health sector, an increase of nearly 4% in annual US health spending ($3.7 trillion in 2019).
Almost as intense efforts are announced in Europe, where the effect of the controversy on the availability of vaccines manufactured by Sanofi has accelerated Franco-German cooperation on Coronabonds.
In the stock market, the biotech sector, the big winner of the crisis, was the first to come out of the water (+9.73% at the end of May), dragging the whole of the health sector in its wake (+3.58%), according to statistics collected by the Quantalys funds observatory.
“The health theme has the advantage of having been more efficient and less risky than that of technology,” emphasizes Jean-François Bay, CEO of Quantalys.
For more stories about biotech and healthcare funds, along with other key financial news stories, download our free companion app, Born2Invest.
Profits up by 5 to 10% per year
Multi-asset managers have increased the weight of the sector in their portfolios, convinced that investments will accelerate even after the crisis. This will fuel the rise in prices.
“The stock market progression, already positive since the beginning of the year, could continue, on the one hand because the sector still has potential to catch up and, on the other hand, because it responds to fundamental megatrends linked to the ageing of the population and the reduction of poverty in the world,” argues Nicolas Deltour, Head of Investor Relations in Equity Strategies at Candriam.
“The growth of healthcare spending is more than proportional to the evolution of a country’s wealth,” he adds.
Edmond de Rothschild AM also reinforces the importance of health in its strategies. “We are convinced that the healthcare sector will maintain its structural sales growth rate of around 5% worldwide with earnings growth of 8 to 10% per year over the next ten years,” says Adeline Salat-Baroux, manager of the Edmond de Rothschild Healthcare fund.
Biotechnology at the cutting edge
Now all eyes are on the most cutting-edge biotechs in the fight against Covid, Moderna Therapeutics, near Boston, run by a Frenchman, and Gilead, a leader in the treatment of HIV and hepatitis C.
Biotech is now driving the growth of a sector that has literally transformed itself since the genetic code was deciphered twenty years ago.
“Over the last ten years, biotech acquisitions or partnerships have enabled laboratories to redirect their research towards biological products such as Sanofi with the acquisitions of Genzyme, Ablynx or, more recently, Synthorx, as well as their partnership with Regeneron,” explains Adeline Salat-Baroux.
As a result, approvals of new compounds were already accelerating before the Covid crisis. “All the products launched over the last three to four years, particularly in oncology, rare diseases and dermatology, will ensure sales growth in the coming years,” says Stéphane Reveau, manager of the Étoile Santé Europe fund, the only PEAble conviction fund in the sector, more than half of which is invested in major European laboratories.
Laboratories have the advantage of bringing stability to managers’ portfolios when biotechs, like Genfit, can plummet if tests disappoint. That Genfit fails in its (large-scale) phase III studies on its treatment for non-alcoholic liver hepatitis (NASH) and the stock plummets.
In biotech “It’s a bit all or nothing,” observes Adeline Salat-Baroux, who balances her fund in all health segments, like other generalist funds such as Étoile Santé Europe.
Stock market growth could therefore continue even if the sector remains sensitive to the programmes and statements of candidates in the US elections.
During the last elections in the United States, the healthcare sector was affected by fears of shrinking budgets, especially since “the US market represents nearly half of the world market in value terms,” points out Stéphane Reveau, manager of the Étoile Santé Europe fund.
But in the end, “Donald Trump did not make any spectacular decisions on the American healthcare system and the sector began a new cycle of outperformance which accelerated at the end of February with the health and economic crisis linked to Covid-19”, he points out.
The managers unanimously dismissed the risk that the return to normal could reduce budgets, believing that they would be “safe”.
Six Selected Health and Biotech Funds
- BGF World Healthscience, BlackRock (Isin Code: LU0171307068)
2020 Performance: + 3.7%
High-performing fund of the US fund manager, where the world’s large caps dominate.
- BNP P. Funds Health Care Innovators, BNP Paribas (Isin Code: LU0823416762)
2020 Performance: +8.50%
Focus on medical innovations and technologies. ESG criteria and conviction management.
- Candriam Eq L Biotech, Candriam Luxembourg (Isin Code: LU1120766388 )
2020 Performance: +9.94%
Highly performing. Invests in biotechnologies mainly in the United States (87% in the United States).
- Edmond de Rothschild, Fund – Healthcare (Isin Code: LU1160356009)
2020 Performance: +4.76%
Actively managed conviction fund. All areas of healthcare. SRI label since May 13.
- Health Star Europe, Étoile Gestion (Isin Code: FR0010541284)
2020 Performance: +1.54%
European stocks in all areas of health (eligible for the PEA until 31/12/2020).
- Pictet-Biotech, Pictet A (Isin Code: LU0255977455)
2020 Performance: +11.9%
Very strong performance. Large biotech stocks for more than half of the fund. Also focuses on mergers.
DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.
This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.
The Jewel of the Crypto Winter: Digital Tokens Backed by Viable Products
The crypto winter that's taken over the market in the last few months has been brutal. Besides tanking prices, there...
What’s New in the Neo-banking Scene in Switzerland?
Swiss neo-banking is becoming increasingly similar to foreign competitors in their product offerings and features. Many are now mimicking the...
Investing Apps: Why Are Retail Investors Using Them?
Investment apps have become increasingly popular among retail investors. Notably, the popularity of investment apps has been triggered by the...
ESG: Tech Companies Must Also Become Responsible
ESG has become vital for many companies in traditional industries like mining. But what are tech companies doing to keep...
Credit for European Companies Cheaper Than a Year Ago Despite Rising Euribor
While market interest rates have seen significant increases, new company financing rates remain lower than they were a year ago....